Expert Says XRP’s Next Leg Will Be Epic. Here’s the Double-digit Target
Crypto pundit Digital Asset Investor has highlighted a bullish XRP price prediction from prominent crypto analyst CrediBULL Crypto. His recent video on X covers a specific price target and the expected timing of XRP’s next major move.
CrediBULL Crypto’s Call
Digital Asset Investor noted that CrediBULL Crypto is among a growing number of chart-focused analysts turning bullish on XRP. CrediBULL stated that XRP is “going to have one of the greatest runs of the cycle, even greater than Ethereum in terms of ROI off the lows.”
CrediBULL’s personal target sits between $20 and $30. Digital Asset Investor set a $15 target on XRP, calling it a good start and signaling his expectation goes well beyond that level. Digital Asset Investor shared this exchange with his audience, highlighting the alignment between multiple analysts on XRP’s potential upside this cycle.
Timing the Next Move
CrediBULL was clear that the major move has not started yet. He described XRP as “not quite ready for that next major leg yet.” He currently recommends holding spot positions and waiting. The suggestion is that patience is required before the anticipated move develops fully.
Digital Asset Investor relayed this position to his audience, reinforcing that the setup is building rather than fully developed. CrediBULL expects the move to be significant when it arrives.
RLUSD Growth Adds to the Picture
CrediBULL’s post Digital Asset Investor referenced shared data showing strong growth in the XRP ecosystem. RLUSD supply has reached a new high of $2.49 billion, up 86% since the start of 2026.
RLUSD is now only $248 million behind PayPal’s PYUSD in total stablecoin supply. PYUSD is down 35% from its peak, while RLUSD grows. A 24-hour market cap chart shows RLUSD added $82.1 million in a single day, making it the second-largest gainer among stablecoins.
Conviction Behind the Target
The $20 to $30 target range reflects strong directional confidence. Digital Asset Investor’s coverage puts CrediBULL’s prediction in front of a large audience at a time when on-chain data already show meaningful growth.
The stablecoin data shows real activity within the XRP ecosystem. For traders following this analysis, the current period represents an accumulation window ahead of what both analysts expect to be a major cycle event.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
